Cerevel’s Acute Anxiety Candidate Shows Encouraging Action In Healthy Volunteers
Cerevel Therapeutics Holdings Inc's (NASDAQ: CERE) 7.5 mg twice daily and the 25 mg twice-daily doses of darigabat
Goldman Sachs Initiates Coverage On Cerevel Therapeutics Hldg with Neutral Rating, Announces Price Target of $27
Goldman Sachs analyst Madhu Kumar initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral rating and announces Price Target of $27.
JP Morgan Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $50
JP Morgan analyst Cory Kasimov initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight rating and announces Price Target of $50.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Cerevel Therapeutics Hldg Q3 EPS $(0.43) Misses $(0.40) Estimate
Cerevel Therapeutics Hldg (NASDAQ:CERE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.40) by 7.5 percent.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Cerevel Therapeutics Announces Departure Of CFO Kathy Yi
Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that Kathy Yi has resigned her position as chief financial officer to